Literature DB >> 4024960

Changes in liver histology during methotrexate therapy of psoriasis correlated to the concentration of methotrexate and folate in erythrocytes.

J Hendel, H Poulsen, B Nyfors, A Nyfors.   

Abstract

To investigate, whether an assessment of the folate and methotrexate concentrations in erythrocytes could be used to indicate incipient histological liver changes, these 2 parameters were related to liver histology in series of liver biopsies (means 4.3 biopsies) from 31 long-term methotrexate-treated psoriasis patients. Logistic regression analysis showed that the probability of changes in liver histology during methotrexate therapy increased significantly with increasing erythrocyte methotrexate concentrations and with decreasing erythrocyte folate concentration. The application of these variables as a decisive criterion when to institute liver biopsy surveillance needs further studies, but can probably help reduce the number of liver biopsies to be taken during long-term methotrexate therapy considerably.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4024960     DOI: 10.1111/j.1600-0773.1985.tb01297.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  4 in total

1.  Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings.

Authors:  M J Ahern; S Kevat; W Hill; P J Hayball; H Harley; P D Hall
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

Review 2.  Hepatotoxicity of methotrexate in rheumatic diseases.

Authors:  S Kevat; M Ahern; P Hall
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

3.  Methotrexate in erythrocytes of patients with psoriasis.

Authors:  H Schrøder; E K Foged
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia.

Authors:  H Schrøder; K Fogh
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.